We are live on ! Find out more
PSTV icon

Plus Therapeutics
PSTV

6 hedge funds and large institutions have $205K invested in Plus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.15% more ownership

Funds ownership: 0.02% → 0.16% (+0.15%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

63% less funds holding

Funds holding: 16 → 6 (-10)

65% less capital invested

Capital invested by funds: $588K → $205K (-$383K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

Holders
6
Holders Change
-10
Holders Change %
-62.5%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$15.4K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$77K
2
Millennium Management
Millennium Management
New York
-$20K
3
Northern Trust
Northern Trust
Illinois
-$16.7K
4
State Street
State Street
Massachusetts
-$9.98K
5
GVAG
Great Valley Advisor Group
Delaware
-$9.74K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$147K -$94 -1 -0%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$34.4K – – –
BlackRock
3
BlackRock
New York
$14.1K – – –
TRCT
4
Tower Research Capital (TRC)
New York
$9.56K +$15.4K +165 +688%
Osaic Holdings
5
Osaic Holdings
Arizona
$268 – – –
Wells Fargo
6
Wells Fargo
California
$36 – – –
Group One Trading
7
Group One Trading
Illinois
$2 – – –
Renaissance Technologies
8
Renaissance Technologies
New York
– -$77K -705 Closed
Millennium Management
9
Millennium Management
New York
– -$20K -186 Closed
Northern Trust
10
Northern Trust
Illinois
– -$16.7K -154 Closed
State Street
11
State Street
Massachusetts
– -$9.98K -92 Closed
GVAG
12
Great Valley Advisor Group
Delaware
– -$9.74K -90 Closed
Creative Planning
13
Creative Planning
Kansas
– -$9.73K -89 Closed
Two Sigma Advisers
14
Two Sigma Advisers
New York
– -$9.31K -86 Closed
TSS
15
Two Sigma Securities
New York
– -$6.8K -63 Closed
ATPW
16
Ashton Thomas Private Wealth
Arizona
– -$3.55K -33 Closed
Fidelity Investments
17
Fidelity Investments
Massachusetts
– -$580 -5 Closed
AF
18
Allworth Financial
California
– -$1 – –
Morgan Stanley
19
Morgan Stanley
New York
– -$3 – –
UBS Group
20
UBS Group
Switzerland
– -$4 – –
UB
21
UMB Bank
Missouri
– -$16 – –

PSTV Hedge Fund Activity: Q2 2023 in Review

6 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q2 2023, worth a combined $205K — down 65% from $588K a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of PSTV and 0 opened new positions — a net loss of 10 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $15.4K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $77K sold.

  • 6 institutional investors held Plus Therapeutics (PSTV) as of Q2 2023, down from 16 in Q1 2023.
  • Funds reported $205K of Plus Therapeutics stock for Q2 2023, down 65% quarter-over-quarter.
  • 0 funds opened new Plus Therapeutics positions in Q2 2023 and 10 closed out, a net change of -10 holders.
  • The largest Plus Therapeutics buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $15.4K added.
  • The largest Plus Therapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $77K sold.

Based on aggregated 13F filings for Q2 2023.